Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Understanding the tumor immune microenvironment (TIME) for effective therapy.

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF.

Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23. Review.

2.

Disentangling the relationship between tumor genetic programs and immune responsiveness.

Bedognetti D, Hendrickx W, Ceccarelli M, Miller LD, Seliger B.

Curr Opin Immunol. 2016 Apr;39:150-8. doi: 10.1016/j.coi.2016.02.001. Epub 2016 Mar 9. Review.

PMID:
26967649
3.

The Role of Tumor Microenvironment in Cancer Immunotherapy.

Frankel T, Lanfranca MP, Zou W.

Adv Exp Med Biol. 2017;1036:51-64. doi: 10.1007/978-3-319-67577-0_4. Review.

PMID:
29275464
4.

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S.

Adv Exp Med Biol. 2017;1036:19-31. doi: 10.1007/978-3-319-67577-0_2. Review.

PMID:
29275462
5.

Immunosuppressive cells in tumor immune escape and metastasis.

Liu Y, Cao X.

J Mol Med (Berl). 2016 May;94(5):509-22. doi: 10.1007/s00109-015-1376-x. Epub 2015 Dec 22. Review.

PMID:
26689709
6.

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.

Oliver AJ, Lau PKH, Unsworth AS, Loi S, Darcy PK, Kershaw MH, Slaney CY.

Front Immunol. 2018 Jan 31;9:70. doi: 10.3389/fimmu.2018.00070. eCollection 2018. Review.

7.

Implications of the tumor immune microenvironment for staging and therapeutics.

Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A.

Mod Pathol. 2018 Feb;31(2):214-234. doi: 10.1038/modpathol.2017.156. Epub 2017 Dec 1. Review.

9.

Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.

Stakheyeva M, Riabov V, Mitrofanova I, Litviakov N, Choynzonov E, Cherdyntseva N, Kzhyshkowska J.

Curr Pharm Des. 2017;23(32):4807-4826. doi: 10.2174/1381612823666170714161703. Review.

PMID:
28714406
10.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

11.

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.

Gajewski TF.

Semin Oncol. 2015 Aug;42(4):663-71. doi: 10.1053/j.seminoncol.2015.05.011. Epub 2015 Jun 3. Review.

12.

Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy.

Moyes KW, Lieberman NA, Kreuser SA, Chinn H, Winter C, Deutsch G, Hoglund V, Watson R, Crane CA.

Hum Gene Ther. 2017 Feb;28(2):200-215. doi: 10.1089/hum.2016.060. Epub 2016 Oct 18. Review.

PMID:
27758144
13.

The immune response in cancer: from immunology to pathology to immunotherapy.

Giraldo NA, Becht E, Vano Y, Saut├Ęs-Fridman C, Fridman WH.

Virchows Arch. 2015 Aug;467(2):127-35. doi: 10.1007/s00428-015-1787-7. Epub 2015 Jun 16. Review.

PMID:
26077464
14.

Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery.

Clancy T, Dannenfelser R, Troyanskaya O, Malmberg KJ, Hovig E, Kristensen V.

Curr Pharm Des. 2017;23(32):4716-4725. doi: 10.2174/1381612823666170710154936. Review.

PMID:
28699527
15.

One microenvironment does not fit all: heterogeneity beyond cancer cells.

Kim IS, Zhang XH.

Cancer Metastasis Rev. 2016 Dec;35(4):601-629. doi: 10.1007/s10555-016-9643-z. Review.

16.

Immunotherapy for Gastric Cancer: Time for a Personalized Approach?

Dolcetti R, De Re V, Canzonieri V.

Int J Mol Sci. 2018 May 29;19(6). pii: E1602. doi: 10.3390/ijms19061602. Review.

17.

Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.

Shahabi V, Postow MA, Tuck D, Wolchok JD.

Am J Clin Oncol. 2015 Feb;38(1):90-7. doi: 10.1097/COC.0b013e3182868ec8. Review.

PMID:
25616204
18.

Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment.

Fransen MF, Arens R, Melief CJ.

Int J Cancer. 2013 May 1;132(9):1971-6. doi: 10.1002/ijc.27755. Epub 2012 Aug 16. Review.

19.

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.

Finn OJ.

Ann Oncol. 2012 Sep;23 Suppl 8:viii6-9. doi: 10.1093/annonc/mds256. Review.

20.

Immunological effect of local ablation combined with immunotherapy on solid malignancies.

Takahashi Y, Matsutani N, Nakayama T, Dejima H, Uehara H, Kawamura M.

Chin J Cancer. 2017 Jun 7;36(1):49. doi: 10.1186/s40880-017-0216-5. Review.

Supplemental Content

Support Center